President Trump announced a price reduction agreement with a global pharmaceutical giant.

On [Date], President Trump announced a price reduction agreement with several global pharmaceutical giants (including Merck, Bristol-Myers Squibb, Novartis, Sanofi, Amgen, Gilead, Boehringer Ingelheim, and Genentech).

As a crucial step in the most-favored-nation pricing policy, these companies have agreed to reduce drug prices for Medicaid programs and cash payments to levels consistent with other affluent countries, while offering substantial discounts through the TrumpRx platform. Simultaneously, the companies have committed to significant U.S. investments and supply chain donations in exchange for a three-year tariff exemption. This move marks an acceleration of the Trump administration's drug pricing reforms, which have already covered 14 top pharmaceutical firms, and is expected to significantly lower the burden on American patients while promoting a rebalancing of global drug prices. Analysis of the impact on market sectors Overall U.S. pharmaceutical industry: The agreement strengthens government intervention in drug pricing. In the short term, pharmaceutical stocks have risen (with most gaining 1%-3% on the announcement day) due to the avoidance of tariff threats and the attainment of policy certainty. However, in the long run, profit margins may be compressed, especially for companies with a high proportion of Medicaid business (such as Gilead). Pharmaceutical firms are shifting to a defensive stance, accelerating investments in domestic manufacturing (totaling over 150 billion dollars), which benefits supply chain localization but may dampen incentives for the development of some high-priced innovative drugs. Industry consolidation may further intensify to address patent cliffs and pricing pressures.

Patient and Health Insurance System

Directly benefiting low-income groups and cash-paying patients, it is expected to save tens of billions of dollars, with significant reductions in specific drugs (such as those for diabetes, cancer, and respiratory conditions) (some exceeding %). After the platform is launched, it will bypass intermediaries and improve accessibility. However, the actual impact depends on the implementation details, as post-discount prices may still be higher than overseas, and not all drugs will be covered.

Global pharmaceutical market

Promoting the end of foreign free-riding may drive countries like Europe to raise drug prices (an agreement has been reached with the UK to increase the net price of new drugs by 25%). The impact on emerging markets such as China is indirect: multinational pharmaceutical companies may raise prices or adopt bundled sales in new markets to offset losses in the U.S., potentially increasing the cost of domestic innovative drugs. However, this also stimulates opportunities for Chinese pharmaceutical companies to expand overseas (e.g., through licensing out) and accelerates local innovation.

Related sectors (such as insurance, ): Trump hints at next step targeting insurers to lower premiums, putting pressure on the health insurance sector. The role of Pharmacy Benefit Managers (PBMs) may weaken due to the rise of direct sales platforms.

This agreement marks a milestone in Trump's drug pricing reform, delivering substantial benefits to American patients while challenging the profit models of pharmaceutical companies. Its impact is expected to gradually emerge starting this year, potentially reshaping the global drug pricing system.

The Trump administration plans to launch a website in the new year, where discounted prescription drugs will be available for consumers to purchase directly.